Skip to main content
Omvoh logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Enrollment Form
Menu closed
Omvoh logo
  • Prescribing Information
  • Medication Guide
  • Instructions for Use
  • Enrollment Form
Globe Loading... Reveal available languages
  • House For Healthcare Providers
    • How Omvoh Works
      • Omvoh for Ulcerative Colitis
      • Who Omvoh Is For
      • Clinical Data
      • Omvoh for Crohn’s Disease
      • Who Omvoh Is For
      • Clinical Data
    • Safety Profile
    • Dosing
    • Support for Your Patients
      • Lilly Support Services
      • Savings Program
      • Getting Omvoh
      • Billing & Coding
      • Prescribing in EHR
    • Resources
  • For Consumers
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Link Visit Lilly Medical (HCP)
Question Sales Inquiry
Question Submit a Question
Chat Click to chat
Expand contact lilly
Orange background with headshot of a hypothetical bio-naive, crohn's disease patient Max.

FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS

Prescribe Omvoh with confidence. Your patients have access to treatment.

Support, Save, and Start on Omvoh:

Enrolling your patients in Lilly Support Services™ for Omvoh can help unlock potential savings* and access support

Enrollment icon

Eligible, commercially insured patients can pay as little as $5† or $0^ per treatment with the Omvoh Savings Program, regardless of insurance denial*

Money icon

Lilly Support Services for Omvoh will help your patients get started and support them through their treatment journey

Person icon

Treatment is defined as one infusion or one 28-day supply of injections.

*Governmental beneficiaries excluded; terms and conditions apply.

†If Omvoh is covered by your commercial drug insurance

^If Omvoh is not covered by your commercial drug insurance

Lilly Support Services for Omvoh can assist patients with the savings program
Call 1-800-LillyRx (1-800-545-5979)

DOWNLOAD ENROLLMENT FORM Right

Your patients can enroll directly in Lilly Support Services with the Lilly Together™ app

To get started, patients can search for “Lilly Together” in the App Store® or on Google Play™ to download the app.

Once signed in, patients can:

  • Set up a treatment plan and reminders.
  • Use symptom tracking to help them view their treatment journey and give you a more complete view of their symptom information all in one place the next time you meet.
  • Connect with a Companion in Care™ team member for ongoing support.
  • *Your Companion in Care provided is not a medical professional
Omvoh copay card

$5 per treatment*

If your patients have commercial insurance that covers Omvoh, they may be eligible to pay as little as $5 per treatment.

$0 per treatment*

If your patients have commercial insurance that does not cover Omvoh, they may be eligible to pay as little as $0 per treatment.

Treatment is defined as one infusion or one 28-day supply of injections.

*Governmental beneficiaries excluded; terms and conditions apply.

By enrolling in the Omvoh Savings Card Program (“Program”) and using the Omvoh Savings Card (“Card”), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Eligibility:

  1. You have been prescribed Omvoh® (mirikizumab-mrkz) for an approved use consistent with FDA approved product labeling;
  2. You are enrolled in a commercial drug insurance plan;
  3. You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program;
  4. You are a resident of the United States or Puerto Rico; and
  5. You are 18 years of age or older.

Program savings for Omvoh infusion

For patients with commercial drug insurance with coverage for Omvoh: You must (a) have coverage for Omvoh through your commercial drug insurance but your insurance does not cover the full cost (i.e., you have a co-pay or coinsurance obligation) and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $5 for each infusion. The Program will cover your co-pay or coinsurance for Omvoh, less $5, up to the maximum monthly, annual, and lifetime limits outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program may provide support for infusions with a date of service that falls within 120 days prior to the date the enrollment form is received by the Program.

To receive Program savings, your healthcare provider must submit a claim for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim, your healthcare provider must then submit an Explanation of Benefits (EOB) form and a CMS 1450 or 1500 form to https://medicalclaimsportal.opushealth.com within 180 days of the infusion date of Omvoh. The submitted form must include the name of the insurer and plan and demonstrate that Omvoh was the medication administered. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

For patients with commercial drug insurance without coverage for Omvoh: You must (a) have commercial drug insurance without coverage for Omvoh, (b) have a prescription for an approved use consistent with FDA-approved product labeling, and (c) be enrolled in the Program on or before the date of the infusion to pay as little as $0 for each infusion. Card may be used for a maximum of up to 3 infusions over the lifetime of the Program. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request for Omvoh to your insurance provider before initiating treatment with Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support Services™ for Omvoh. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

Program savings for Omvoh injections

For patients with commercial drug insurance with coverage for Omvoh: You must have commercial drug insurance that covers Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $5 per month for Omvoh injections. Month is defined as 28-days and up to 1 fill. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization upon enrollment in the Program. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program savings no later than 12/31/2025.

For patients with commercial drug insurance without coverage for Omvoh: You must have commercial drug insurance without coverage for Omvoh and a prescription consistent with FDA-approved product labeling to pay as little as $0 per month for Omvoh injections. Month is defined as 28 days and up to 1 fill. Program savings are subject to maximum monthly, annual, and lifetime limits, outlined below. Card may be used for a maximum of up to 14 prescription fills of the injection per calendar year. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. To receive Program savings, your healthcare provider must submit a prior authorization (PA) request for Omvoh to your insurance provider prior to your 1st fill of Omvoh and provide the results of the PA demonstrating your insurance provider has denied coverage for non-administrative reasons to Lilly Support Services™ for Omvoh. To continue receiving Program savings, your healthcare provider must submit an appeal of the denial of coverage to your insurance provider prior to your 5th fill and provide the results of the appeal demonstrating your provider has denied coverage for non-administrative reasons to Lilly Support Services™ for Omvoh. To remain eligible for the Program, a new PA, appeal, or medical exception must be submitted prior to the 13th fill and as required by Lilly at its sole discretion. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions, and you first utilize the Program benefits no later than 12/31/2025.

Monthly, annual, and lifetime maximum savings for the Program

Program savings are limited to a maximum of 30 months.

For patients with commercial drug insurance with coverage for Omvoh: Program savings for claims covered under the medical and/or pharmacy portion of your medical insurance for Omvoh are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum annual savings of $9,200 for each calendar year. Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.

For patients with commercial drug insurance without coverage for Omvoh: Program savings for claims not covered under the medical and/or pharmacy portion of your medical insurance are limited to up to 3 infusions over the lifetime of the Program and up to 14 injection fills per calendar year, subject to a combined (injection and infusion) maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual maximum savings. Monthly and annual maximums are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Omvoh Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Omvoh, you are not eligible for and are prohibited from using the Omvoh Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member’s use of Omvoh Savings Card Program. You agree to inform Omvoh Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximum savings are set at Lilly’s sole and absolute discretion and may be changed by Lilly with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Omvoh, only allows partial coverage for Omvoh, removes coverage for Omvoh and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Omvoh, or does not apply Card payments to satisfy your
co-payment, deductible, or coinsurance for Omvoh.

Program savings are limited to the co-pay or coinsurance costs for Omvoh only, subject to a monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Program will only be accepted at participating pharmacies. Patients with commercial drug insurance without coverage for Omvoh must use Lilly’s designated pharmacy vendor to obtain Program savings. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Omvoh Savings Card and agree to call Lilly Support Services™ for Omvoh at
1-800-LillyRx (1-800-545-5979) to stop participation. Card activation is required. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Omvoh. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these terms and conditions. Eligibility criteria, and terms and conditions for the Omvoh Savings Card Program may change from time to time; the most current version can be found at https://www.omvoh.lilly.com/savings-support. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason, savings may continue until 06/30/2028 or for up to 30 months whichever comes first, provided you continue to meet the Program’s terms and conditions and you first utilize the Program benefits no later than 12/31/2025.

TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

Learn more about the savings program
access the buy and bill portal

Access the Buy and Bill Portal

Collect patient-cost sharing Right

Hospital icon

Access Support

  • Managing both medical and pharmacy benefits investigation and providing next steps navigating the insurance process
  • Identifying payer requirements for in-network infusion site and in-network specialty pharmacies
  • Determining out-of-pocket costs if benefits investigation is requested
  • Initiating the Savings Program* for eligible, commercially insured patients

*Governmental beneficiaries excluded; terms and conditions apply.

Savings Card Icon

Ongoing support services

  • Confirming continued eligibility for the Omvoh Savings Program*
  • Suggesting useful resources that may help patients understand their condition
  • Offering injection training and sharps disposal container

*Governmental beneficiaries excluded; terms and conditions apply.

syringe icon

Injection training

  • Free of charge to patients and their families
  • Patients can choose either virtual or telephone training
  • Nurse Educator-led face to face video and telephonic injection training
  • View Injection training video
Nurse icon

Live, one-on-one support for your patients

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET
  • Nurse Educators will provide support for patients during the IV to SC transition
Omvoh Digital Starter Kit icon

Digital Starter Kit

  • Everything patients need to get started on Omvoh
  • Free and simple to send and download
  • Text OMV to 85099
sharps container icon

Sharps disposal support

Allows patients to safely dispose of Omvoh devices. Once the container is full, your patients can mail it back and contact Lilly Support Services™ to receive another one.

Prescribing Omvoh

Benefits Investigation

Get help with preliminary insurance investigation, in network infusion sites, and specialty pharmacy identification with Lilly Support Services™ for Omvoh.

CoverMyMeds®

PA assistance available through CoverMyMeds for patients where a PA request is required.

Omvoh Pharmacy Network

Omvoh is available through contracted specialty pharmacies and authorized distributors.

How to procure Omvoh Vials for induction?

Omvoh vials are available for purchase through Lilly Authorized Distributors of Record.

Lilly Trade

Lilly Patient Support Provider Portal

With the Lilly Patient Support Provider Portal, office sites are able to digitally enroll patients in Lilly Support Services™ for Omvoh, and utilize services to help with access and coverage assistance.

Lilly Patient Support Provider Portal

J-Code available

J-Code Available For Use: J2267

IMPORTANT SAFETY INFORMATION for Omvoh (mirikizumab-mrkz)

Warning:

CONTRAINDICATIONS - Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with Omvoh administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction. If a severe hypersensitivity reaction occurs, discontinue Omvoh immediately and initiate appropriate treatment.

Infections

Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing Omvoh. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer Omvoh until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Omvoh. Do not administer Omvoh to patients with active TB infection. Initiate treatment of latent TB prior to administering Omvoh. Consider anti-TB therapy prior to initiation of Omvoh in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after Omvoh treatment. In clinical trials, subjects were excluded if they had evidence of active TB, a history of active TB, or were diagnosed with latent TB at screening.

Hepatotoxicity

Drug-induced liver injury in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. Omvoh was discontinued. Liver test abnormalities eventually returned to baseline. Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management. Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Immunizations

Avoid use of live vaccines in patients treated with Omvoh. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with Omvoh.

ADVERSE REACTIONS

Most common adverse reactions associated with Omvoh (≥2% of subjects and at a higher frequency than placebo) in ulcerative colitis treatment are upper respiratory tract infections and arthralgia during the induction study (UC-1), and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during the maintenance study (UC-2).

Most common adverse reactions associated with Omvoh in the Crohn’s disease study (CD-1) (≥5% of subjects and at a higher frequency than placebo) are upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.

Omvoh injection is available as a 300mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information.

MR HCP ISI CD APP

Please see Prescribing Information and Medication Guide for Omvoh. Please see Instructions for Use included with the device.

INDICATIONS

Ulcerative Colitis
Omvoh is an interleukin-23 antagonist indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Crohn's Disease
Omvoh is an interleukin-23 antagonist indicated for the treatment of moderately to severely active Crohn's disease (CD) in adults.

  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

To speak to a customer specialist:
Call 1-800-LillyRx
(1-800-545-5979)

This site is intended for US healthcare providers.

Omvoh® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Support Services™, Lilly Together™, and Companion in Care™ are trademarks owned by Eli Lilly and Company. Other product/company names mentioned herein are the trademarks of their respective owners.

PP-MR-US-0001 04/2025 ©Lilly USA, LLC 2025. All rights reserved.

Your Privacy Choices

Cookie Settings

Terms of Use Privacy Statement Consumer Health Privacy Notice Accessibility Statement Sitemap
Eli Lilly Logo